UniProtKB/Swiss-Prot Q7Z333 : Variant p.Trp305Cys
Probable helicase senataxin
Feedback ?
Variant information
Variant position:
305
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
305 (W305C, p.Trp305Cys).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution).following page
Variant description:
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
305
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
2677
The length of the canonical sequence.
Location on the sequence:
W GQLMDPIVAFQTIINNASYN
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human PFWPALHCFMVILDRLGSKVW GQLMDPIVAFQTIINNASYN
Mouse PFWPALHCFMVILDRLGSKVW GQLIDPIEAFQTIINNESYN
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 2677 Probable helicase senataxin
Literature citations
Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2.
Moreira M.-C.; Klur S.; Watanabe M.; Nemeth A.H.; Le Ber I.; Moniz J.-C.; Tranchant C.; Aubourg P.; Tazir M.; Schoels L.; Pandolfo M.; Schulz J.B.; Pouget J.; Calvas P.; Shizuka-Ikeda M.; Shoji M.; Tanaka M.; Izatt L.; Shaw C.E.; M'Zahem A.; Dunne E.; Bomont P.; Benhassine T.; Bouslam N.; Stevanin G.; Brice A.; Guimaraes J.; Mendonca P.; Barbot C.; Coutinho P.; Sequeiros J.; Duerr A.; Warter J.-M.; Koenig M.;
Nat. Genet. 36:225-227(2004)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1); TISSUE SPECIFICITY; VARIANT CYS-1152; VARIANTS SCAN2 CYS-305; TRP-332; LEU-413; SER-1756 AND LEU-2213; INVOLVEMENT IN ALS4;
A SUMO-dependent interaction between Senataxin and the exosome, disrupted in the neurodegenerative disease AOA2, targets the exosome to sites of transcription-induced DNA damage.
Richard P.; Feng S.; Manley J.L.;
Genes Dev. 27:2227-2232(2013)
Cited for: FUNCTION; INTERACTION WITH EXOSC9 AND UBE2I; SUMOYLATION; SUBCELLULAR LOCATION; CHARACTERIZATION OF VARIANTS SCAN2 CYS-305 AND LEU-413; CHARACTERIZATION OF VARIANTS ALS4 ILE-3 AND SER-389; MUTAGENESIS OF GLU-65;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.
